Ladenburg Thalmann Initiates Coverage on Invivo Therapeutics Holdings Corp(NASDAQ:NVIV). The shares have been rated Buy. The rating by Ladenburg Thalmann was issued on Jul 21, 2016.
In a different note, Raymond James said it Initiates Coverage on Invivo Therapeutics Holdings Corp, according to a research note issued on Jul 7, 2016. The shares have been rated ‘Strong Buy’ by the firm.
Invivo Therapeutics Holdings Corp (NVIV) made into the market gainers list on Wednesdays trading session with the shares advancing 1.41% or 0.09 points. Due to strong positive momentum, the stock ended at $6.48, which is also near the day’s high of $6.52. The stock began the session at $6.45 and the volume stood at 64,528 shares. The 52-week high of the shares is $17.19 and the 52 week low is $3.5. The company has a current market capitalization of $207 M and it has 3,19,08,054 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Aug 14, 2015, C Ann Merrifield (director) purchased 2,000 shares at $12.36 per share price.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company’s technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children’s Hospital (BCH) and the Massachusetts Institute of Technology (MIT) and intellectual property that has been developed internally including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.